The Registration Program of BRCA1/2 Gene

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

8000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-10-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose:

1. Screening of large samples is to search the gene mutation of the breast cancer susceptibility gene (BRCA1 and BRCA2) in Chinese high risk group.
2. To build the breast cancer BRCA1/2 mutation database of Chinese group.
3. To build the hazard model of breast cancer BRCA1/2 mutation of Chinese group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Testing BRCA 1/2 Mutation Using Next Generation Sequencing

NCT02151747

Breast Neoplasms Breast Cancer

COMPLETED

Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

NCT01034033

Breast Cancer Ovarian Cancer Gynecologic Cancers +1 more

RECRUITING

Genotyping 2 SNPs in Chinese Breast Cancers

NCT02886845

rs185670819 and rs183489969

UNKNOWN

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

NCT00858078

BRCA1 Gene BRCA2 Gene

COMPLETED

A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration

NCT06564428

Ovarian Neoplasms

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is the first large-scale and systematic study that fully recognize and review on the mutation spectrum of BRCA1/2 and the risk of Breast cancer in Chinese high risk group, it will be a Landmark research of susceptibility genes in Chinese breast cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No treatment

There will be two groups, one is breast cancer patient group, another group inlude the first-degree relatives and second degree relatives of patients with BRCA1/2 mutation. All volunteers should provid tissue(s) and blood for NGS test.

NGS test

Intervention Type GENETIC

To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.

To know mutation characteristic spectrum of BRCA1/2.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NGS test

To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.

To know mutation characteristic spectrum of BRCA1/2.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients: it must be from independent family and meet the one or more of the following conditions.

1. Patients' age at diagnosis: 45 years or younger.
2. Patients' age at diagnosis: 50 years or younger.
3. Breast cancer patients: it must meet the one or more of the following family medical histories.

3.1 Patients' age at diagnosis: 50 years or younger, and the one or more of the next of Kin has breast cancer.

3.2 Patients' age at diagnosis: any of age, and the one or more of the next of Kin has breast cancer that its age at diagnosis was 50 years or younger.

3.3 Patients' age at diagnosis: any of age, and the two or more of the next of Kin have breast cancer that its age at diagnosis was 50 years or younger.

3.4 Patients' age at diagnosis: any of age, and the one or more of the next of Kin has epithelial ovarian cancer.

3.5 Patients' age at diagnosis: any of age, and the two or more of the next of Kin have pancreatic cancer and/or prostate cancer (Gleason grading\>7, any of age).

3.6 Patients' age at diagnosis: any of age, and the one or more of the close-male relatives has breast cancer.
4. Triple negative patients' age of onset: 60 years or younger.
5. Patients: male and have breast cancer.

Patients' first or second degree relatives are BRCA1/2 mutation carrier (1-5 people):

First or second degree female adult relatives of patients (age: 18 years or older), it will be selected from the same paternal or maternal side according to the family disease.

First or second degree male relatives of patients have breast cancer.